Page last updated: 2024-10-18

glycine and Depression

glycine has been researched along with Depression in 22 studies

Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.

Research Excerpts

ExcerptRelevanceReference
"Our findings suggest that skeletal muscular glycine contributes to the antidepressant effects of ketamine in inflammation."7.91Contribution of skeletal muscular glycine to rapid antidepressant effects of ketamine in an inflammation-induced mouse model of depression. ( Hua, D; Hua, F; Huang, N; Jiang, R; Li, S; Luo, A; Wang, Y; Wu, Y; Yang, C; Yang, L; Yu, F; Zhan, G; Zhu, B, 2019)
"We measured the serum levels of d-serine, l-serine, glycine, glutamate and glutamine in patients with depression (n=70), and age-matched healthy subjects (n=78)."7.83Increased serum levels of serine enantiomers in patients with depression. ( Enohara, M; Fujita, Y; Hasegawa, T; Hashimoto, K; Hashimoto, T; Ishikawa, M; Iyo, M; Kanahara, N; Kimura, A; Nakazato, M; Niitsu, T; Sasaki, T; Shiina, A; Watanabe, H; Yoshida, T, 2016)
"Glycine was well tolerated, resulted in significantly increased serum glycine levels and induced a mean 36 (7%) reduction in negative symptoms (P < 0."6.68Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. ( Ermilov, M; Heresco-Levy, U; Horowitz, A; Javitt, DC; Kelly, D; Mordel, C, 1996)
"Glycine's effect was blocked by strychnine, a GlyR antagonist, indicating that it was mediated by strychnine-sensitive GlyRs."5.51Activation of glycine receptors in the lateral habenula rescues anxiety- and depression-like behaviors associated with alcohol withdrawal and reduces alcohol intake in rats. ( Fu, R; Li, W; Ndukwe, M; Wu, L; Wu, W; Ye, JH; Zhang, H; Zuo, QK; Zuo, W, 2019)
" MDD patients had significantly higher serum levels of glutamic acid, aspartic acid and glycine but lower levels of 3-Hydroxykynurenine; glutamic acid and phenylalanine levels also correlated with depression severity."4.31The Utility of Amino Acid Metabolites in the Diagnosis of Major Depressive Disorder and Correlations with Depression Severity. ( Ching, J; Ho, CSH; Tay, GWN; Wee, HN, 2023)
"Our findings suggest that skeletal muscular glycine contributes to the antidepressant effects of ketamine in inflammation."3.91Contribution of skeletal muscular glycine to rapid antidepressant effects of ketamine in an inflammation-induced mouse model of depression. ( Hua, D; Hua, F; Huang, N; Jiang, R; Li, S; Luo, A; Wang, Y; Wu, Y; Yang, C; Yang, L; Yu, F; Zhan, G; Zhu, B, 2019)
"We measured the serum levels of d-serine, l-serine, glycine, glutamate and glutamine in patients with depression (n=70), and age-matched healthy subjects (n=78)."3.83Increased serum levels of serine enantiomers in patients with depression. ( Enohara, M; Fujita, Y; Hasegawa, T; Hashimoto, K; Hashimoto, T; Ishikawa, M; Iyo, M; Kanahara, N; Kimura, A; Nakazato, M; Niitsu, T; Sasaki, T; Shiina, A; Watanabe, H; Yoshida, T, 2016)
"The purpose of this study is to explore depression metabolic markers in rat hippocampus and to investigate the anti-depressant effect of genipin and its mechanisms using nuclear magnetic resonance (NMR) metabonomics."3.80[1H NMR based metabonomics study on the antidepressant effect of genipin in rat hippocampus]. ( Gao, S; Peng, GJ; Qin, XM; Shi, BY; Tian, JS, 2014)
"Glycine was well tolerated, resulted in significantly increased serum glycine levels and induced a mean 36 (7%) reduction in negative symptoms (P < 0."2.68Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. ( Ermilov, M; Heresco-Levy, U; Horowitz, A; Javitt, DC; Kelly, D; Mordel, C, 1996)
"Glycine's effect was blocked by strychnine, a GlyR antagonist, indicating that it was mediated by strychnine-sensitive GlyRs."1.51Activation of glycine receptors in the lateral habenula rescues anxiety- and depression-like behaviors associated with alcohol withdrawal and reduces alcohol intake in rats. ( Fu, R; Li, W; Ndukwe, M; Wu, L; Wu, W; Ye, JH; Zhang, H; Zuo, QK; Zuo, W, 2019)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19904 (18.18)18.7374
1990's5 (22.73)18.2507
2000's1 (4.55)29.6817
2010's8 (36.36)24.3611
2020's4 (18.18)2.80

Authors

AuthorsStudies
Ho, CSH1
Tay, GWN1
Wee, HN1
Ching, J1
Liu, M1
He, J1
Ruan, C1
Pan, W1
Mao, P1
Sun, Z1
Wang, G1
Yang, J1
Li, G1
Zhao, M1
Cheng, X1
Zhao, T1
Feng, Z1
Zhao, Y1
Fan, M1
Zhu, L1
Zhao, S1
Chi, A1
Yan, J1
Yao, C1
Cattani, D1
Cesconetto, PA1
Tavares, MK1
Parisotto, EB1
De Oliveira, PA1
Rieg, CEH1
Leite, MC1
Prediger, RDS1
Wendt, NC1
Razzera, G1
Filho, DW1
Zamoner, A1
Li, W1
Zuo, W1
Wu, W1
Zuo, QK1
Fu, R1
Wu, L1
Zhang, H1
Ndukwe, M1
Ye, JH1
Huang, N1
Wang, Y1
Zhan, G1
Yu, F1
Li, S2
Hua, D1
Jiang, R1
Wu, Y1
Yang, L1
Zhu, B1
Hua, F1
Luo, A1
Yang, C1
Moskal, JR1
Burch, R1
Burgdorf, JS1
Kroes, RA1
Stanton, PK1
Disterhoft, JF1
Leander, JD1
Peng, GJ1
Shi, BY1
Tian, JS1
Gao, S1
Qin, XM1
Khojasteh, F1
Nahavandi, A1
Mehrpouya, S1
Homberg, JR1
Mirzamohammadi, S1
Raufi, S1
Soleimani, M1
Barati, M1
Hashimoto, K1
Yoshida, T1
Ishikawa, M1
Fujita, Y1
Niitsu, T1
Nakazato, M1
Watanabe, H1
Sasaki, T1
Shiina, A1
Hashimoto, T1
Kanahara, N1
Hasegawa, T1
Enohara, M1
Kimura, A1
Iyo, M1
Wider, C1
Dachsel, JC1
Farrer, MJ1
Dickson, DW1
Tsuboi, Y1
Wszolek, ZK1
WEINBERG, MM1
Peskov, AB1
Maevskii, EI1
Uchitel', ML1
Sakharova, NY1
Vize-Khripunova, MA1
Bonkowsky, HL1
Schady, W1
Nowak, G1
Paul, IA1
Popik, P1
Young, A1
Skolnick, P1
Berlin, I1
Said, S1
Spreux-Varoquaux, O1
Olivares, R1
Launay, JM1
Puech, AJ1
Leiderman, E1
Zylberman, I1
Zukin, SR1
Cooper, TB1
Javitt, DC2
Heresco-Levy, U1
Ermilov, M1
Mordel, C1
Horowitz, A1
Kelly, D1
Naylor, JM1
Leibel, T1
Middleton, DM1
Plotnikoff, NP1
Kastin, AJ1
Anderson, MS1
Schally, AV1
Ressler, C1
Koga, T1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070]68 participants (Actual)Interventional2007-08-31Completed
Pilot Study of Glycine Augmentation in Carriers of a Mutation in the Gene Encoding Glycine Decarboxylase[NCT01720316]Phase 22 participants (Actual)Interventional2012-12-10Completed
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine[NCT02304432]Early Phase 12 participants (Actual)Interventional2015-09-27Completed
Controlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical Ventilation[NCT04443673]59 participants (Actual)Interventional2020-06-15Terminated (stopped due to An interim analysis showed no difference in major outcomes (n=35 glycine and n=24 control participants))
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Auditory Evoked Potentials - P50 Ratio (P50 S2/P50 S1 Amplitude) at 1) BASELINE - Pre-glycine Treatment and 2) IN WEEK 6 OF GLYCINE TREATMENT

Auditory evoked potentials amplitude: P50 ratio (S2/S1). Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine

Interventionratio (Number)
Auditory ERPs Amplitude (Deg) Baseline: Subject 244.51
Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 235.67

Auditory Evoked Potentials in Amplitude (Degrees Measured in Microvolts) at 1) BASELINE - Pre-glycine Treatment and 2) IN WEEK 6 OF GLYCINE TREATMENT

Auditory evoked potentials amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2 amplitude; mismatch negativity (MMN) at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine

,
Interventionmicrovolts (Number)
P300 amplitude at fzP300 amplitude at czP300 amplitude at pzN100 amplitude at fzN100 amplitude at czP200 amplitude at fzP200 amplitude at czP50 S1 amplitudeP50 S2 amplitudeMMN amplitude at fzMMN amplitude at cz
Auditory ERPs Amplitude (Deg) 6 Weeks of Glycine: Subject 23.746.65.57-4.71-3.896.297.82.20.78-1.004-1.322
Auditory ERPs Amplitude (Deg) Baseline: Subject 2-0.6356.535.34-3.93-3.621.6626.592.761.23-3.356-4.13

Auditory Evoked Potentials in Gammas Oscillations (the Power Spectrum is Measured in Microvolts Squared) at 1) BASELINE - Pre-glycine Treatment and 2) IN WEEK 6 OF GLYCINE TREATMENT

Auditory evoked potentials gamma: G40 hz phase locking at fz and cz; G20 hz phase locking response at fz and cz G30 hz phase locking response at fz and cz. Participants were assessed at baseline and in week 6 of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine

,
Interventionmicrovolts squared (Number)
G40 fzG40 czG20 fzG20 czG30 fzG30 cz
Auditory ERPs Gamma 6 Weeks of Glycine: Subject 20.2550.290.1070.1080.1770.242
Auditory ERPs Gamma Baseline: Subject 20.1350.1680.0230.030.190.163

Auditory Evoked Potentials in Latency (Msec) at BASELINE - Pre-glycine Treatment and 2) IN WEEK 6 OF TREATMENT WITH GLYCINE

Auditory evoked potentials latency: P300 at fz, cz, and pz); N100 at fz and cz); P200 at fz and cz. Participants were assessed at baseline and in week of open-label glycine treatment. (NCT01720316)
Timeframe: Recordings at baseline and week 6 of glycine

,
Interventionmsec (Number)
P300 latency at fzP300 latency at czP300 latency at pzN100 latency at fzN100 latency at czP200 latency at fzP200 latency at cz
Auditory ERPs Latency (ms) 6 Weeks of Glycine: Subject 2300.78293294.929494205203
Auditory ERPs Latency (ms) Baseline: Subject 2279.3279.3279.397.6691.8197.27193.4

Brain GABA Metabolite Levels (GABA/Creatine Ratio: GABA/Cr) at 1) BASELINE - Pre-glycine Treatment and 2) IN WEEK 6 OF GLYCINE TREATMENT

Magnetic resonance spectroscopy GABA/Cr. Participants were assessed 1) pre-glycine treatment (baseline) and 2) in week 6 of open-label glycine treatment measured in posterior occipital cortex. (NCT01720316)
Timeframe: Baseline and week 6 of glycine

,
Interventionratio (Number)
Baseline GABA/CrWeek 6 of glycine tx GABA/Cr
Subject1: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine0.160.22
Subject2: Brain GABA/CR Ratio- Baseline/Week 6 of Glycine0.270.24

Brain Glutamate Metabolite Levels (Glutamate/Creatine Ratio: Glu/Cr) at 1) BASELINE - Pre-glycine Treatment and 2) IN WEEK 6 OF GLYCINE TREATMENT

magnetic resonance spectroscopy - glutamate metabolite level. Participants were assessed 1) pre-glycine treatment and in week 6 of open-label glycine treatment. Measured in posterior occipital cortex. (NCT01720316)
Timeframe: baseline and week 6 of glycine

,
Interventionratio (Number)
Baseline brain glutamate/Cr ratioWeek 6 brain glutamate/Cr ratio
Subject1: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine0.980.84
Subject2: Brain Glutamate/CR Ratio- Baseline/Week 6 of Glycine2.0531.13

Brain Glycine/CR Ratio

magnetic resonance spectroscopy: glycine/creatine ratio. Participants were assessed at 1) BASELINE PRE-GLYCINE TREATMENT: pre-glycine challenge drink, 60 minutes post challenge drink, 80 minutes post challenge drink, 100 minutes post challenge drink, and 120 minutes post challenge drink (0.4 g/kg up to max of 30 g); and 2) IN WEEK 6 OF OPEN-LABEL GLYCINE TREATMENT: pre-glycine dose, and 60 minutes, 80 minutes, 100 minutes and 120 minutes post daily dose of glycine. Measured in posterior occipital cortex (NCT01720316)
Timeframe: baseline (pre-challenge, 60, 80, 100, 120 minutes post-challenge), and week 6 of glycine (pre-dose and 60, 80, 100, 120 minutes post-dose

,
Interventionratio (Number)
Baseline - pre-challenge drinkBaseline 60 minutes post challenge drinkBaseline 80 minutes post challenge drinkBaseline 100 minutes post challenge drinkBaseline 120 minutes post challenge drinkWeek 6 of glycine - pre-glycine doseWeek 6 of glycine - 60 minutes post glycine doseWeek 6 of glycine - 80 minutes post glycine doseWeek 6 of glycine - 100 minutes post glycine doseWeek 6 of glycine - 120 minutes post glycine dose
Subject 2:Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine0.56910.39180.64280.63630.95590.32350.38070.55910.41420.3545
Subject1: Brain Glycine/CR Ratio at Baseline/Week 6 of Glycine0.25580.61570.66310.59380.69530.65730.29830.45770.57510.3842

Brief Psychiatric Rating Scale (BPRS) Scores at Baseline and at 2 Weeks, 4 Weeks, and 6 Weeks Positive and Negative Symptom Scores at Baseline and at 2, 4, and 6 Weeks During Intervention 1, Intervention 2, and During Open-label Glycine

Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within and after each treatment period

,
Interventionunits on a scale (Number)
BPRS at baselineBPRS at 2 weeks intervention 1BPRS at 4 weeks intervention 1BPRS at 6 weeks intervention 1BPRS, end of washout1BPRS at 2 weeks intervention 2BPRS at 4 weeks intervention 2BPRS at 6 weeks intervention 2BPRS, end of washout2BPRS at 2 weeks open labelBPRS at 4 weeks open labelBPRS at 6 weeks open labelBPRS, end of washout3
Glycine, Then Placebo39383221223731373223222119
Placebo, Then Glycine46383928343220232420181923

Clinical Global Impression (CGI) Severity Scores at Baseline and at 2 Weeks, 4 Weeks, and 6 Weeks Within Each Treatment Period

Clinical Global Impression (CGI) severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT01720316)
Timeframe: CGI at baseline and at 2 weeks, 4 weeks, and 6 weeks per treatment period

,
Interventionunits on a scale (Number)
CGI severity score at baselineCGI severity score at 2 weeks intervention 1CGI severity score at 4 weeks intervention 1CGI severity score at 6 weeks intervention 1CGI severity score, end of washout1CGI severity score at 2 weeks intervention 2CGI severity score at 4 weeks intervention 2CGI severity score at 6 weeks intervention 2CGI severity score, end of washout2CGI severity score at 2 weeks open labelCGI severity score at 4 weeks open labelCGI severity score at 6 weeks open labelCGI severity score, end of washout3
Glycine, Then Placebo4432244443322
Placebo, Then Glycine4444444333322

Clinical Global Impression (CGI) Therapeutic Effect Scores at 2 Weeks, 4 Weeks, and 6 Weeks Within Each Treatment Period

Clinical Global Impression (CGI) therapeutic effect scores measure degree of improvement as marked (1), moderate (5), minimal (9) or unchanged/worse (13). (NCT01720316)
Timeframe: at 2 weeks, 4 weeks, and 6 weeks within each treatment period

,
Interventionscore (Number)
CGI therapeutic effect at 2 weeks intervention 1CGI therapeutic effect at 4 weeks intervention 1CGI therapeutic effect at 6 weeks intervention 1CGI therapeutic effect, end of washout1CGI therapeutic effect at 2 weeks intervention 2CGI therapeutic effect at 4 weeks intervention 2CGI therapeutic effect at 6 weeks intervention 2CGI therapeutic effect, end of washout2CGI therapeutic effect at 2 weeks open labelCGI therapeutic effect at 4 weeks open labelCGI therapeutic effect at 6 weeks open labelCGI therapeutic effect, end of washout3
Glycine, Then Placebo13555131313135511
Placebo, Then Glycine5555135551111

Depression Symptom Scores at Baseline and at 2 Weeks, 4 Weeks, and 6 Weeks Within Each Treatment Period

Hamilton Depression Scale measures severity of depression symptoms. The sum of ratings for 9 depression symptoms are measured on a scale from 0-2 with 0 meaning no symptoms and 2 meaning some level of severity of that specific symptom. The rating for 1 depression symptom is measured on a scale from 0-3 with 0 meaning no symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms are measured on a scale from 0-4 with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period

,
Interventionunits on a scale (Number)
Depression symptoms at baselineDepression symptoms at 2 weeks intervention 1Depression symptoms at 4 weeks intervention 1Depression symptoms at 6 weeks intervention 1Depression symptoms, end of washout1Depression symptoms at 2 weeks intervention 2Depression symptoms at 4 weeks intervention 2Depression symptoms at 6 weeks intervention 2Depression symptoms, end of washout2Depression symptoms at 2 weeks open labelDepression symptoms at 4 weeks open labelDepression symptoms at 6 weeks open labelDepression symptoms, end of washout3
Glycine, Then Placebo18171131195732212
Placebo, Then Glycine12550332111110

Glycine Plasma Amino Acid Levels at Baseline, During Glycine Treatment, During Placebo Treatment and During Open-label Glycine

Plasma glycine levels; normal range is 122-467 nM/mL (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine

,
InterventionnM/mL (Number)
BaselineGlycine double-blindPlaceboGlycine open-label
Glycine Then Placebo216410194516
Placebo Then Glycine271761347634

Mania Symptom Scores at Baseline and at 2 Weeks, 4 Weeks, and 6 Weeks Within Each Treatment Period

Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of ratings for 7 symptoms of mania is measured on a scale from 0-4 and the sum of 4 symptoms of mania is measured on a scale from 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period

,
Interventionunits on a scale (Number)
Manic symptoms at baselineManic symptoms at 2 weeks intervention 1Manic symptoms at 4 weeks intervention 1Manic symptoms at 6 weeks intervention 1Manic symptoms, end of washout1Manic symptoms at 2 weeks intervention 2Manic symptoms at 4 weeks intervention 2Manic symptoms at 6 weeks intervention 2Manic symptoms, end of washout2Manic symptoms at 2 weeks open labelManic symptoms at 4 weeks open labelManic symptoms at 6 weeks open labelManic symptoms, end of washout3
Glycine, Then Placebo41000170221000
Placebo, Then Glycine7760000000000

Neurocognitive Function at Baseline, During Glycine Treatment, During Placebo Treatment and During Open-label Glycine

Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution; standard deviation of 10. Only overall composite score is entered. (NCT01720316)
Timeframe: At baseline, during glycine treatment, during placebo treatment and during open-label glycine

,,,
Interventionunits on a scale (Number)
Participant 1Participant 2
Baseline4548
Composite Score on Glycine, Double-blind5252
Composite Score on Glycine, Open-label4946
Composite Score on Placebo5255

Positive and Negative Symptom Scores at Baseline and at 2 Weeks, 4 Weeks, and 6 Weeks During Intervention 1 (Glycine or Placebo), Intervention 2 (Glycine or Placebo), and During Open-label Glycine

Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms are measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT01720316)
Timeframe: baseline and at 2 weeks, 4 weeks, and 6 weeks within each treatment period and after each treatment period

,
Interventionunits on a scale (Number)
Positive symptoms at baselinePositive symptoms at 2 weeks intervention 1Positive symptoms at 4 weeks intervention 1Positive symptoms at 6 weeks intervention 1Positive symptoms, end of washout1Positive symptoms at 2 weeks intervention 2Positive symptoms at 4 weeks intervention 2Positive symptoms at 6 weeks intervention 2Positive symptoms, end of washout2Positive symptoms at 2 weeks open labelPositive symptoms at 4 weeks open labelPositive symptoms at 6 weeks open labelPositive symptoms, end of washout3
Glycine, Then Placebo1312987121114149977
Placebo, Then Glycine1920191313121011118788

Auditory Evoked Potentials - P50 Ratio (P50 S2/S1) (Amplitude)

Auditory evoked potential amplitude: P50 ratio (P50 S2/S1) (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment

Interventionratio (Number)
P50 ratio: BaselineP50 ratio: Week 8 of DCS
First Open Label DCS44.5130

Auditory Evoked Potentials in Amplitude (Degrees Measured in Microvolts)

Auditory evoked potential amplitude: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz; P50 S1 and S2; mismatch negativity (MMN) at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment

Interventionmicrovolts (Number)
P300 at fz: BaselineP300 at cz: BaselineP300 at pz: BaselineN100 at fz: BaselineN100 at cz: BaselineP200 at fz: BaselineP200 at cz: BaselineP50 S1: BaselineP50 S2: BaselineMMN at fz: BaselineMMN at cz: BaselineP300 at fz: Week 8 of DCSP300 at cz: Week 8 of DCSP300 at pz: Week 8 of DCSN100 at fz: Week 8 of DCSN100 at cz: Week 8 of DCSP200 at fz: Week 8 of DCSP200 at cz: Week 8 of DCSP50 S1: Week 8 of DCSP50 S2: Week 8 of DCSMMN at fz: Week 8 of DCSMMN at cz: Week 8 of DCS
First Open Label DCS-0.6356.5295.340-3.926-3.6151.6626.5912.7591.23-3.356-4.1303.0306.8106.620-3.260-3.9408.2008.1601.360.4-3.330-1.540

Auditory Evoked Potentials in Gamma Oscillations (the Power Spectrum is Measured in Microvolts Squared)

Auditory evoked potential gamma: G40 hz phase locking at fz and cz; G30 hz phase locking at fz and cz; G20 hz phase locking at fz and cz (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment

Interventionmicrovolts squared (Number)
G40 hz phase locking at fz: BaselineG40 hz phase locking at cz: BaselineG30 hz phase locking at fz: BaselineG30 hz phase locking at cz: BaselineG20 hz phase locking at fz: BaselineG20 hz phase locking at cz: BaselineG40 hz phase locking at fz: Week 8 of DCSG40 hz phase locking at cz: Week 8 of DCSG30 hz phase locking at fz: Week 8 of DCSG30 hz phase locking at cz: Week 8 of DCSG20 hz phase locking at fz: Week 8 of DCSG20 hz phase locking at cz: Week 8 of DCS
First Open Label DCS0.1350.1680.1900.1630.0230.0300.3440.3810.1680.190.01-0.01

Auditory Evoked Potentials in Latency (Msec)

Auditory evoked potential latency: P300 at fz, cz, and pz; N100 at fz and cz; P200 at fz and cz. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment

Interventionmsec (Number)
P300 at fz: BaselineP300 at cz: BaselineP300 at pz: BaselineN100 at fz: BaselineN100 at cz: BaselineP200 at fz: BaselineP200 at cz: BaselineP300 at fz: Week 8 of DCSP300 at cz: Week 8 of DCSP300 at pz: Week 8 of DCSN100 at fz: Week 8 of DCSN100 at cz: Week 8 of DCSP200 at fz: Week 8 of DCSP200 at cz: Week 8 of DCS
First Open Label DCS279.297279.297279.29797.65691.797197.266193.359294.920294.00029487.988.000212.890212.000

Brain Glycine/CR Ratio

Proton magnetic resonance spectroscopy at 4T: brain glycine/CR ratio. Participants were assessed at baseline (pre-glycine challenge dose and 60, 80, 100 and 120 minutes post glycine dose) and in week 8 of of open-label DCS treatment: pre-DCS dose, and 60, 80, 100 and 120 minutes post DCS dose. Measured in posterior occipital cortex. (NCT02304432)
Timeframe: Baseline and Week 8 of DCS treatment

Interventionratio (Median)
BaselineBaseline at 60 minutesBaseline at 80 minutesBaseline at 100 minutesBaseline at 120 minutesWeek 8 of DCS: BaselineWeek 8 of DCS: 60 minutesWeek 8 of DCS: 80 minutesWeek 8 of DCS: 100 minutesWeek 8 of DCS: 120 minutes
Open Label DCS0.412450.503750.652950.615050.82560.109770.2488850.326090.320520.312155

Brief Psychiatric Rating Scale (BPRS) Scores

Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2

,
Interventionunits on a scale (Median)
Baseline BPRS2 weeks BPRS4 weeks BPRS6 weeks BPRS8 weeks BPRS10 weeks BPRS12 weeks BPRS14 weeks BPRS16 weeks BPRS18 weeks BPRS20 weeks BPRS22 weeks BPRS24 weeks BPRS
First Open Label DCS3725262424.5NANANANANANANANA
Second Open Label DCS31.530.52825.52626.52625.528.5272524.526.5

Brief Psychiatric Rating Scale (BPRS) Scores

Total BPRS score measures severity of 18 psychiatric symptoms. Each symptom is scored 1-7 with the total score ranging from 18-126. 18 means no symptoms and 126 means very severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)

,
Interventionunits on a scale (Number)
Baseline BPRS for first intervention2 weeks BPRS for first intervention4 weeks BPRS for first intervention6 weeks BPRS for first interventionBaseline BPRS for second intervention2 weeks BPRS for second intervention4 weeks BPRS for second intervention6 weeks BPRS for second intervention
DCS First, Then Placebo2625252639454538
Placebo First, Then DCS2935333536302728

Clinical Global Impression (CGI) Severity Scores

CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2

,
Interventionunits on a scale (Median)
Baseline CGI2 weeks CGI4 weeks CGI6 weeks CGI8 weeks CGI10 weeks CGI12 weeks CGI14 weeks CGI16 weeks CGI18 weeks CGI20 weeks CGI22 weeks CGI24 weeks CGI
First Open Label DCS42222NANANANANANANANA
Second Open Label DCS2.52.52.52.52.532.522.52.52.52.52.5

Clinical Global Impression (CGI) Severity Scores

CGI severity scores measure severity of mental illness on a scale of 1-7 where 1 means normal, not at all ill, 2 means borderline mentally ill, 3 means mildly ill, 4 means moderately ill, 5 means markedly ill, 6 means severely ill and 7 means among the most extremely ill patients. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)

,
Interventionunits on a scale (Number)
Baseline CGI for first intervention2 weeks CGI for first intervention4 weeks CGI for first intervention6 weeks CGI for first interventionBaseline CGI for second intervention2 weeks CGI for second intervention4 weeks CGI for second intervention6 weeks CGI for second intervention
DCS First, Then Placebo22223333
Placebo First, Then DCS13333222

Depression Symptom Scores

Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2

,
Interventionunits on a scale (Median)
Baseline HAM2 weeks HAM4 weeks HAM6 weeks HAM8 weeks HAM10 weeks HAM12 weeks HAM14 weeks HAM16 weeks HAM18 weeks HAM20 weeks HAM22 weeks HAM24 weeks HAM
First Open Label DCS51.510.51.5NANANANANANANANA
Second Open Label DCS0.51102.50003.50000

Depression Symptom Scores

Hamilton Depression Scale (HAM) measures severity of depression symptoms. The sum of the ratings for 9 depression symptoms is measured on a scale of 0-2 with 0 meaning no depression symptoms and 2 meaning some level of severity of that specific symptom. The rating for one depression symptom is measured on a scale of 0-3 with 0 meaning no depression symptoms and 3 meaning a severe level of that specific symptom. The sum of ratings for 11 depression symptoms is measured on a scale of 0-4, with 0 meaning no symptoms and 4 meaning a severe level of that specific symptom. The three sums are added to produce an overall depression rating scale score ranging from 0-65. Higher scores indicate worse depression symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)

,
Interventionunits on a scale (Number)
Baseline HAM for first intervention2 weeks HAM for first intervention4 weeks HAM for first intervention6 weeks HAM for first interventionBaseline HAM for second intervention2 weeks HAM for second intervention4 weeks HAM for second intervention6 weeks HAM for second intervention
DCS First, Then Placebo010021292
Placebo First, Then DCS452100000

Mania Symptom Scores

Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2

,
Interventionunits on a scale (Median)
Baseline YMRS2 weeks YMRS4 weeks YMRS6 weeks YMRS8 weeks YMRS10 weeks YMRS12 weeks YMRS14 weeks YMRS16 weeks YMRS18 weeks YMRS20 weeks YMRS22 weeks YMRS24 weeks YMRS
First Open Label DCS21100NANANANANANANANA
Second Open Label DCS0000000000001

Mania Symptom Scores

Young Mania Rating Scale (YMRS) measures severity of manic symptoms. The sum of the ratings for 7 symptoms of mania is measured on a scale of 0-4 and the sumof 4 symptoms of mania is measured on a scale of 0-8 to yield a total score ranging from 0-60, with 0 meaning no manic symptoms and 60 meaning severe manic symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)

,
Interventionunits on a scale (Number)
Baseline YMRS for first intervention2 weeks YMRS for first intervention4 weeks YMRS for first intervention6 weeks YMRS for first interventionBaseline YMRS for second intervention2 weeks YMRS for second intervention4 weeks YMRS for second intervention6 weeks YMRS for second intervention
DCS First, Then Placebo00000000
Placebo First, Then DCS10004111

Neurocognitive Function

Scores on each of 8 domains of cognitive function (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning/problem solving, social cognition, overall composite). Scores are T scores ranging from 0-100, with 50 representing the mean for a population based on a normal distribution, standard deviation of 10. Higher scores signify better functioning. (NCT02304432)
Timeframe: Baseline and Week 8 of open-label DCS treatment

InterventionT scores (Median)
Baseline Processing SpeedBaseline Attention/VigilanceBaseline Working MemoryBaseline Verbal LearningBaseline Visual LearningBaseline Reasoning/Problem SolvingBaseline Social CognitionBaseline Overall Composite ScoreWeek 8 of open-label DCS Processing SpeedWeek 8 of open-label DCS Attention/VigilanceWeek 8 of open-label DCS Working MemoryWeek 8 of open-label DCS Verbal LearningWeek 8 of open-label DCS Visual LearningWeek 8 of open-label DCS Reasoning/Problem SolvingWeek 8 of open-label DCS Social CognitionWeek 8 of open-label DCS Overall Composite Score
Open Label DCS48.544.538.55450.552.54846.552.547.550.543.554.566.544.551.5

Positive and Negative Symptom Scores

Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline & at 2, 4, 6 & 8 Weeks during open-label phase 1 and every 2 weeks up to 24 weeks during open label phase 2

,
Interventionunits on a scale (Median)
Baseline positiveBaseline negative2 weeks positive2 weeks negative4 weeks positive4 weeks negative6 weeks positive6 weeks negative8 weeks positive8 weeks negative10 weeks positive10 weeks negative12 weeks positive12 weeks negative14 weeks positive14 weeks negative16 weeks positive16 weeks negative18 weeks positive18 weeks negative20 weeks positive20 weeks negative22 weeks positive22 weeks negative24 weeks positive24 weeks negative
First Open Label DCS14.514.5101210.512912912NANANANANANANANANANANANANANANANA
Second Open Label DCS1114111410.513.59139.51210.5131112101210.51210.51210.5129.5121012

Positive and Negative Symptom Scores

Positive and Negative Symptom Scale (PANSS) measures positive and negative symptoms of schizophrenia. The sum of ratings for seven positive symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms.The sum of ratings for seven negative symptoms is measured on a scale from 7-49 with 7 meaning no symptoms and 49 meaning severe symptoms. (NCT02304432)
Timeframe: Baseline, 2, 4, & 6 weeks (crossover periods)

,
Interventionunits on a scale (Number)
Baseline positive for first interventionBaseline negative symptoms for first intervention2 weeks positive for first intervention2 weeks negative for first intervention4 weeks positive for first intervention4 weeks negative for first intervention6 weeks positive for first intervention6 weeks negative for first interventionBaseline positive for second interventionBaseline negative for second intervention2 weeks positive for second intervention2 weeks negative for second intervention4 weeks positive for second intervention4 weeks negative for second intervention6 weeks positive for second intervention6 weeks negative for second intervention
DCS First, Then Placebo10151015101510151518151815181418
Placebo First, Then DCS11912151113131313131011911911

Reviews

2 reviews available for glycine and Depression

ArticleYear
GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:2

    Topics: Animals; Antidepressive Agents; Cognition; Depression; Excitatory Amino Acid Agonists; Glycine; Huma

2014
Neurologic manifestations of acute porphyria.
    Seminars in liver disease, 1982, Volume: 2, Issue:2

    Topics: Acute Disease; Aminolevulinic Acid; Animals; Central Nervous System; Depression; Electrophysiology;

1982

Trials

3 trials available for glycine and Depression

ArticleYear
Succinate-based preparation alleviates manifestations of the climacteric syndrome in women.
    Bulletin of experimental biology and medicine, 2005, Volume: 140, Issue:3

    Topics: Adult; alpha-Tocopherol; Anxiety; Blood Glucose; Climacteric; Depression; Female; Food Additives; Fu

2005
Monoamine oxidase A and B activities in heavy smokers.
    Biological psychiatry, 1995, Dec-01, Volume: 38, Issue:11

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Blood Platelets; Blood Pressure; Cotinine; Depression;

1995
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
    The British journal of psychiatry : the journal of mental science, 1996, Volume: 169, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Cross-Over Studies; Depression; Double-Blind Method; Drug Therap

1996

Other Studies

17 other studies available for glycine and Depression

ArticleYear
The Utility of Amino Acid Metabolites in the Diagnosis of Major Depressive Disorder and Correlations with Depression Severity.
    International journal of molecular sciences, 2023, Jan-23, Volume: 24, Issue:3

    Topics: Amino Acids; Aspartic Acid; Biomarkers; Depression; Depressive Disorder, Major; Glutamic Acid; Glyci

2023
Simultaneous measurement of amino acid enantiomers in the serum of late-life depression patients using convenient LC-MS/MS method with N
    Journal of pharmaceutical and biomedical analysis, 2023, Jun-15, Volume: 230

    Topics: Amino Acids; Chromatography, High Pressure Liquid; Chromatography, Liquid; Depression; Dinitrobenzen

2023
FG-4592 Improves Depressive-Like Behaviors through HIF-1-Mediated Neurogenesis and Synapse Plasticity in Rats.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020, Volume: 17, Issue:2

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Glycine; Hippocampus; Hypoxia-Inducibl

2020
Feature of Heart Rate Variability and Metabolic Mechanism in Female College Students with Depression.
    BioMed research international, 2020, Volume: 2020

    Topics: Adolescent; Autonomic Nervous System; Depression; Fatigue; Female; Glycine; Heart Rate; Humans; Meta

2020
Developmental exposure to glyphosate-based herbicide and depressive-like behavior in adult offspring: Implication of glutamate excitotoxicity and oxidative stress.
    Toxicology, 2017, 07-15, Volume: 387

    Topics: Acetylcholinesterase; Age Factors; Animals; Astrocytes; Behavior, Animal; Binding Sites; Cholinergic

2017
Activation of glycine receptors in the lateral habenula rescues anxiety- and depression-like behaviors associated with alcohol withdrawal and reduces alcohol intake in rats.
    Neuropharmacology, 2019, Volume: 157

    Topics: Action Potentials; Alcohol Drinking; Animals; Anxiety; Behavior, Animal; Depression; Glycine; Habenu

2019
Contribution of skeletal muscular glycine to rapid antidepressant effects of ketamine in an inflammation-induced mouse model of depression.
    Psychopharmacology, 2019, Volume: 236, Issue:12

    Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Glycine; Inflammation; Ketamine;

2019
[1H NMR based metabonomics study on the antidepressant effect of genipin in rat hippocampus].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2014, Volume: 49, Issue:2

    Topics: Alanine; Animals; Antidepressive Agents; Aspartic Acid; Behavior, Animal; Chronic Disease; Depressio

2014
Cognitive impairment induced by permanent bilateral common carotid occlusion exacerbates depression-related behavioral, biochemical, immunological and neuronal markers.
    Brain research, 2015, Jan-30, Volume: 1596

    Topics: Analysis of Variance; Animals; Carotid Artery Diseases; Chromatography, High Pressure Liquid; Cognit

2015
Increased serum levels of serine enantiomers in patients with depression.
    Acta neuropsychiatrica, 2016, Volume: 28, Issue:3

    Topics: Adult; Biomarkers; Case-Control Studies; Depression; Female; Glutamic Acid; Glutamine; Glycine; Huma

2016
Elucidating the genetics and pathology of Perry syndrome.
    Journal of the neurological sciences, 2010, Feb-15, Volume: 289, Issue:1-2

    Topics: Adult; Age of Onset; Aged; Animals; Brain; Chlorocebus aethiops; COS Cells; Depression; DNA-Binding

2010
Aminoacetic acid (glycine) in the treatment of depression.
    The Journal of nervous and mental disease, 1945, Volume: 102

    Topics: Depression; Depressive Disorder; Glycine; Humans

1945
Ca2+ antagonists effect an antidepressant-like adaptation of the NMDA receptor complex.
    European journal of pharmacology, 1993, Sep-15, Volume: 247, Issue:1

    Topics: Animals; Antidepressive Agents; Binding Sites; Calcium Channel Blockers; Cerebral Cortex; Depression

1993
Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.
    Biological psychiatry, 1996, Feb-01, Volume: 39, Issue:3

    Topics: Administration, Oral; Adult; Antipsychotic Agents; Depression; Dose-Response Relationship, Drug; Dru

1996
Effect of glutamine or glycine containing oral electrolyte solutions on mucosal morphology, clinical and biochemical findings, in calves with viral induced diarrhea.
    Canadian journal of veterinary research = Revue canadienne de recherche veterinaire, 1997, Volume: 61, Issue:1

    Topics: Animals; Cattle; Cattle Diseases; Depression; Diarrhea; Electrolytes; Feces; Fluid Therapy; Glutamin

1997
Deserpidine antagonism by a tripeptide, L-prolyl-L-leucyglycinamide.
    Neuroendocrinology, 1973, Volume: 11, Issue:1

    Topics: Animals; Depression; Dihydroxyphenylalanine; Disease Models, Animal; Dose-Response Relationship, Dru

1973
-cyanoamino acids and related nitriles as inhibitors of glutamate decarboxylase.
    Biochimica et biophysica acta, 1971, Aug-20, Volume: 242, Issue:2

    Topics: Acetates; Amino Acids; Aminobutyrates; Animals; Carbon Isotopes; Carboxy-Lyases; Chickens; Cyanides;

1971